Results 301 to 310 of about 61,821 (357)

From Lock-and-Key to Velcro: Glycan-Dependent T Cell Recruiter Redefines Cancer Cell Targeting With Density-Dependent Recognition. [PDF]

MedComm (2020)
Wei P, Tong A, Zhao L.
europepmc   +1 more source

Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report. [PDF]

Case Rep Oncol
Uemura Y, Togitani K, Nakashima J.
europepmc   +1 more source

The making of bispecific antibodies [PDF]

MAbs, 2017
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Ulrich Brinkmann, Roland E Kontermann
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Bispecific Antibodies for the Treatment of Neuroblastoma

SSRN Electronic Journal, 2022
Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton, Nai-Kong V, Cheung   +1 more
openaire   +2 more sources

Engineering bispecific antibodies

Current Opinion in Biotechnology, 1993
Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire   +2 more sources

Bispecific Antibodies in Lymphoma

International Reviews of Immunology, 1993
info:eu-repo/semantics ...
Brissinck, J, Demanet, Christian, Moser, Muriel, Leo, Oberdan, Thielemans, Kris   +4 more
openaire   +3 more sources

A revival of bispecific antibodies

Trends in Biotechnology, 2004
Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Peter, Kufer, Ralf, Lutterbüse, Patrick A, Baeuerle   +2 more
openaire   +2 more sources

Production of Bispecific Antibodies

Current Protocols in Immunology, 1995
AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire   +2 more sources

Design and Production of Bispecific Antibodies [PDF]

Antibodies, 2019
With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells.
Qiong Wang, Yiqun Chen, Jaeyoung Park
exaly   +4 more sources